๐ข Recruiting
Phase 1
๐ Investigational Drug / Biologic
NCT06043713
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
๐ Fred Hutch/University of Washington Cancer Consortium โ Seattle, Washington
View Study & Checklist โ